064|China’s 3SBio gains a North American foothold, CAR-T patient death and more

by • September 12, 2017 • Feature Slider, Feature-Home, Featured-Slides-Home, PodcastComments Off on 064|China’s 3SBio gains a North American foothold, CAR-T patient death and more119

China’s 3SBio puts its North American campaign into high gear with the $290 million purchase of Mississauga’s Therapure BioPharma.

Merck’s cladribine tablet, Mavenclad achieves sustained control of relapsing multiple sclerosis.

And the death of a patient enrolled in a CART- study puts Cellectis’ work on an off-the-shelf CAR-T therapy on hold.

The Biotechnology Focus, Stratford Managers, and BioTalent Canada 2017 biotechnology employee survey has been extended to September 22.

These are the stories we have for you on the latest episode of the Biotechnology Focus podcast.

 

To read the stories in full, click on the links below:

CHINESE BIOPHARMA 3SBIO SNAPS UP CANADA’S THERAPURE IN US$290-M DEAL

Mavenclad Cladribine tablets from Merck

MERCK’S CLADRIBINE TABLETS SHOW SUSTAINED DISEASE CONTROL

CAR-T THERAPY ON HOLD AFTER PATIENT DEATH

Comments are closed.